The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics.

The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along ...

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

Nimble sells the Fold 3-in-1 Wireless Charger exclusively through the Apple Store, both online and in person. It comes in ...

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical ...